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Arteriovenous graft thrombosis is a frequent event in
hemodialysis patients, and usually occurs in grafts with
significant underlying stenosis. Regular surveillance for graft
stenosis, with pre-emptive angioplasty of significant lesions,
may improve graft outcomes. This prospective, randomized,
clinical trial allocated 126 hemodialysis patients with grafts to
either clinical monitoring alone (control group) or to regular
ultrasound surveillance for graft stenosis every 4 months in
addition to clinical monitoring (ultrasound group). The two
randomized groups were closely matched with respect to
demographic, clinical, and graft characteristics, with the
exception of a lower frequency of diabetes in the ultrasound
group. The primary outcome was graft survival, and the
secondary outcome was thrombosis-free graft survival. The
frequency of pre-emptive graft angioplasty was 64% higher
in the ultrasound group than in the control group (1.05 vs
0.64 events per patient-year, Po0.001), whereas the
frequency of thrombosis was not different (0.67 vs 0.78 per
patient-year, P¼ 0.37). The median time to permanent graft
failure was similar between the two groups (38 vs 37 months,
P¼ 0.93). Likewise, the median time to graft thrombosis or
failure did not differ (22 vs 25 months, P¼ 0.33). There was
no significant association between diabetes and time to graft
failure (P¼ 0.93) or time to graft thrombosis or failure
(P¼ 0.88). In conclusion, the addition of regular ultrasound
surveillance for graft stenosis to clinical monitoring increases
the frequency of pre-emptive angioplasty, but may not
decrease the likelihood of graft failure or thrombosis.
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Although fistulas are preferred to grafts for vascular access,1
over 50% of US hemodialysis patients still use arteriovenous
grafts.2 Thrombosis is the most common cause of arterio-
venous graft failure.3 Graft thrombosis is usually super-
imposed on a hemodynamically significant stenosis, raising
the plausible hypothesis that pre-emptive angioplasty of
critical graft stenosis may prevent graft thrombosis, and
thereby increase graft longevity.4 This hypothesis appears to
be supported by a number of observational studies reporting
substantial decreases in the frequency of graft thrombosis,
after implementing a monitoring program for early detection
of graft stenosis.5–9 These programs include clinical monitor-
ing, as well as a variety of surveillance methods, including
periodic access flow monitoring, measurement of static
dialysis venous pressures, and Duplex ultrasound. The official
position taken by the National Kidney Foundation Kidney
Diseases Quality Initiative NKF-K/DOQI guidelines is that all
hemodialysis units should implement graft surveillance
programs, and refer patients with suspected graft stenosis
for pre-emptive angioplasty.10
However, several recent randomized clinical trials evalua-
ting graft surveillance have cast doubt on these recommend-
ations. Specifically, surveillance for graft stenosis using
Duplex ultrasound,11,12 access flow monitoring,12,13 or static
dialysis venous pressures14 did not prolong the time to first
graft thrombosis or permanent graft failure, as compared to a
control group without graft surveillance. These studies have
been criticized as having inadequate statistical power, using
inappropriate criteria for referral for a fistulogram, or for
performing technically unsatisfactory angioplasties. Thus, the
benefit of graft surveillance and pre-emptive angioplasty
remains controversial.15
For the past 9 years, we have been using clinical
monitoring to screen for graft stenosis.16 Patients with
suspected graft stenosis have been referred for diagnostic
fistulograms. The purpose of the present study was to
evaluate, in a randomized clinical trial, whether implement-
ation of a graft surveillance program with Duplex ultrasound
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in addition to clinical monitoring would decrease graft
thrombosis or increase graft longevity, as compared with
clinical monitoring alone.
RESULTS
Over a 3-year period, we randomized 126 subjects into the
study. Of those, 61 were randomized to continue with
routine clinical monitoring, and 65 were randomized to
receive Duplex ultrasound surveillance of their grafts every 4
months in addition to routine clinical monitoring. Six
subjects in the ultrasound group (9%) declined to have
ultrasounds performed after their randomization, but
continued to have their end points followed according to
the ‘intent-to-treat’ protocol. The baseline demographic and
clinical characteristics of the study patients are summarized
in Table 1. The two groups did not differ significantly in their
age, sex, race, or co-morbidities, with the exception of a lower
frequency of diabetes in the ultrasound group. In addition,
the grafts in both treatment groups were similar in their age,
location and frequency of previous interventions.
In the control group, an angioplasty was triggered by an
abnormal physical examination in about 20% of cases,
unexplained decrease of Kt/V in about 30% of cases and
hemodialysis abnormalities in about 50% (Table 2). In the
ultrasound patients, an angioplasty was triggered by an
abnormal ultrasound in three-quarters of the cases, with the
remainder due to abnormalities of clinical monitoring.
In patients referred for a fistulogram due to an abnormal
Duplex ultrasound, an angioplasty was performed 80% of the
time (Table 3). The positive predictive value of an
abnormality in clinical monitoring was somewhat lower at
70%, with abnormal physical examination having a positive
predictive value for stenosis comparable to that of Duplex
ultrasound, whereas hemodialysis or Kt/V abnormalities had
a lower predictive value. The positive predictive value varied
substantially (from 30 to 76%) for various subtypes of
hemodialysis abnormalities. The percent graft stenosis was
reduced from 67712 to 25715% (Po0.001) after the
angioplasty. Similarly, the intra-graft to systemic pressure
ratio was decreased significantly following angioplasty
(0.5670.18 to 0.2970.11, Po0.0001).
The mean follow-up time was 21.9 months in the
ultrasound group and 22.9 months in the control group.
The median follow-up time was 22 months in the ultrasound
group and 24 months in the control group (P¼ 0.72). The
overall frequency of pre-emptive graft angioplasty was
substantially higher (by 64%) in the ultrasound group, as
compared with the control group (Table 4). In contrast, the
Table 1 | Baseline characteristics of the randomized groups
Variable Ultrasound group Control group P-value
N patients 65 61
Demographics
Age (years) 57712 58713 0.61
Sex
Female 34 (52%) 40 (66%) 0.13
Male 31 (48%) 21 (34%)
Race
Black 61 (94%) 60 (98%) 0.20
White 4 (6%) 1 (2%)
Serum albumin (g/dl) 3.870.4 3.770.3 0.45
Dry weight (kg) 79718 81722 0.99
Co-morbidities
Diabetes 34 (52%) 43 (70%) 0.045
CAD 14 (21%) 15 (25%) 0.83
CHF 15 (23%) 9 (15%) 0.26
CVD 8 (12%) 10 (16%) 0.61
HTN 60 (92%) 59 (97%) 0.44
PVD 5 (8%) 10 (6%) 0.17
Features of graft
Graft location
Forearm 11 (17%) 18 (30%) 0.09
Upper arm 54 (83%) 43 (70%)
Graft age (days) 2677221 2737191 0.86
Previous PTA 22 (34%) 19 (31%) 0.75
Previous thrombectomy 20 (31%) 14 (23%) 0.32
‘Virgin’ graftsa 29 (47.5%) 28 (43.1%) 0.72
Values are mean7s.d. or percent.
CAD, coronary artery disease; CHF, congestive heart failure; CVD, cerebrovascular
disease; HTN, hypertension; PTA, percutaneous transluminal angioplasty; PVD,
peripheral vascular disease.
aGrafts without previous angioplasty, thrombectomy, or surgical revision.
Table 2 | Reasons for graft PTA
Indication Ultrasound group Control group
US 97 0
PE 12 16
Kt/V 4 23
HD 14 37
Total 127 76
HD, abnormalities observed during the hemodialysis session; Kt/V, unexplained
decrease in delivered Kt/V; PE, abnormality in physical examination; PTA,
percutaneous transluminal angioplasty; US, abnormal Duplex ultrasound.
Table 3 | Predictive value of screening tests for graft stenosis
Test
No. of
fistulograms
No. requiring
PTA
Positive
predictive value
of test (%)
US 122 97 80
Clinical monitoring 151 106 70
PE 35 28 80
Kt/V 39 27 69
HD 77 51 66
HD subcategories
Prolonged bleeding 46 35 76
Difficult cannulation 12 7 58
Aspiration of clots 10 3 30
Fist, fistulogram; HD, abnormalities observed during the hemodialysis session; Kt/V,
unexplained decrease in delivered Kt/V; PE, abnormality in physical examination;
PTA, percutaneous transluminal angioplasty; US, abnormal Duplex ultrasound.
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frequency of graft thrombosis and surgical revision during
study follow-up was similar between the two randomized
groups.
The reasons for study termination in the two randomized
groups are summarized in Figure 1. About 40% of the
subjects in each group had a permanent graft failure. Of the
27 graft failures in the ultrasound group, 18 were due to
thrombosis, and nine to infection. Of the 26 graft failures in
the control group, 21 were due to thrombosis and five due to
infection. The remaining subjects were followed until their
death, kidney transplant, change in renal replacement
modality, transfer to a non-participating dialysis facility
or completion of the study. One patient switched electively
to home peritoneal dialysis, and one withdrew consent
for participation in the study several months after randomi-
zation.
The cumulative graft survival was similar between the two
groups (median survival, 38 vs 37 months for the ultrasound
and control groups, respectively) (Figure 2). The hazard ratio
for graft failure in the ultrasound group was 0.93 (95% CI
[0.53, 1.64]). Likewise, the thrombosis-free graft survival was
similar for the two groups (22 vs 25 months, for the
ultrasound and control groups, respectively) (Figure 3). The
hazard ratio for graft thrombosis in the ultrasound group was
1.13 (95% CI, [0.71, 1.81]). A subgroup analysis restricted to
patients with ‘virgin’ grafts (those without angioplasty,
thrombectomy or surgical revision before randomization)
revealed no significant difference with respect to time to graft
failure (P¼ 0.32) or thrombosis-free survival (P¼ 0.72).
Because the two groups were not comparable with respect
to the proportion of patients with diabetes, the impact of this
factor on the intervention group comparison was explored
with respect to time to graft failure and time to graft
thrombosis or failure. There was no statistically significant
association between diabetes and graft survival (P¼ 0.93) or
thrombosis-free survival (P¼ 0.88). In addition, there was no
significant association between graft age at the time of
enrollment and graft survival (P¼ 0.89) or thrombosis-free
survival (P¼ 0.22).
DISCUSSION
Both clinical monitoring and ultrasound surveillance had a
high positive predictive value for detecting significant graft
stenosis (Table 3). As expected, graft stenosis was detected
more frequently in the group monitored by both ultrasound
and clinical monitoring, as compared with the control group,
which received only clinical monitoring. However, despite
more frequent interventions for stenosis, neither graft
longevity nor thrombosis-free graft survival was improved
in the ultrasound group. In other words, ultrasound
Table 4 | Frequency of graft procedures
Procedure
Ultrasound
group Control group P-value
Pre-emptive PTA/year (95% CI) 1.05 (0.88–1.25) 0.64 (0.51–0.81) o0.001
Thromboses/year (95% CI) 0.67 (0.53–0.84) 0.78 (0.63–0.96) 0.37
Surgical revisions/year (95% CI) 0.13 (0.06–0.20) 0.16 (0.17–0.37) 0.31
The frequencies were calculated by dividing the total number of procedures by the
total number of years of follow-up. P-values were calculated using the exact test for
homogeneity of Poisson rates.
PTA, percutaneous transluminal angioplasty.
Patients screened
(N=133)
Duplex ultrasound + 
clinical monitoring
(N=65)
Clinical monitoring
(N=61)
126 randomly allocated
Exclusion criteria (N=5)
Refused consent (N=2)
Died (N=19) 
Translplanted (N=6) 
Relocated to another unit (N=0)
Changed to home dialysis (N=0) 
Withdrew from study (N=1) 
Graft loss (N=27)
Died (N=10) 
Translplanted (N=3) 
Relocated to another unit (N=5)
Changed to home dialysis (N=1) 
Withdrew from study (N=0) 
Graft loss (N=26)
Figure 1 | Flow diagram of randomized clinical trial of clinical
monitoring vs clinical monitoring plus regular ultrasound
surveillance for stenosis, looking at graft failure and thrombosis.
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Figure 2 | Comparison of cumulative graft survival between
randomized patients with clinical monitoring vs clinical
monitoring plus regular ultrasound surveillance of grafts.
P¼ 0.93 by the log-rank test.
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Figure 3 | Comparison of thrombosis-free graft survival between
randomized patients with clinical monitoring vs clinical
monitoring plus regular ultrasound surveillance of grafts.
P¼ 0.33 by the log-rank test.
732 Kidney International (2006) 69, 730–735
o r i g i n a l a r t i c l e ML Robbin et al.: Comparison of ultrasound surveillance and clinical monitoring
surveillance was quite successful in identifying graft stenosis;
the problem was that pre-emptive angioplasty did not
improve graft patency.
Whereas abnormalities detected during graft monitoring
have a high positive predictive value for significant
stenosis,6–8,17 they are far less predictive of subsequent graft
thrombosis.18,19 This means that a substantial proportion of
grafts with significant stenosis by radiologic criteria are not at
risk for subsequent thrombosis. Because there are no reliable
tests to distinguish between stenotic grafts that are at risk of
thrombosis and those that are not, all stenotic grafts are
subjected to angioplasty. This means that many of these
patients undergo unnecessary interventions. This might still
be considered an acceptable tradeoff if the effect was to
decrease the overall likelihood of graft thrombosis or failure
in the population of hemodialysis patients dialyzing with
grafts.
One possible explanation for the lack of benefit with
regular ultrasound surveillance is that the graft angioplasties
were technically unsuccessful. This explanation seems
unlikely, as we have documented a substantial improvement
in both the magnitude of stenosis and the intra-access to
systemic pressure ratio following angioplasty. A second
potential explanation is that graft stenosis recurs rapidly
despite a technically successful angioplasty. Two recent
publications have provided evidence for this possibility.
When access blood flows were measured before and after
angioplasty of a graft stenosis, the access blood flow failed to
increase in 21% of grafts after 1 week and in 40% of grafts
after 1 month.13,20 Furthermore, there is no significant
correlation between the change in access blood flow and
change in percent stenosis after an angioplasty.21 A possible
pathophysiologic explanation for the high recurrence rate of
stenosis is provided by a recent study that observed
accelerated myointimal hyperplasia following angioplasty of
vascular access.22 It is also possible that the use of stents
might improve the outcomes of grafts following angio-
plasty,23,24 thereby making ultrasound surveillance more
beneficial. A randomized trial in which stents are employed
to treat graft stenosis is warranted.
Several observational studies have reported substantial
reductions in the rate of graft thrombosis after implement-
ation of a program of graft monitoring with pre-emptive
angioplasty of stenotic lesions.5–9 In contrast, four previous
randomized clinical trials have not observed a difference in
cumulative graft survival and thrombosis-free survival in
patients monitored with a standardized surveillance method
(access blood flow, static dialysis venous pressure or stenosis
monitoring by ultrasound) as compared with control patients
undergoing clinical monitoring alone.11–14 As was the case in
the present study, each of these four studies documented a
substantially higher frequency of pre-emptive angioplasties in
the experimental than in the control group, but this did not
translate into an improvement in graft outcomes.
A recent randomized trial reported by Malik et al.25
observed an increase in graft survival in patients undergoing
ultrasound surveillance. The frequency of ultrasound sur-
veillance in Malik et al.’s study (every 3 months) was similar
to that in the present study (every 4 months). Malik et al.’s
study enrolled only incident grafts, whereas we enrolled
prevalent grafts. It is possible that ultrasound surveillance is
primarily beneficial for incident grafts; however, this seems
unlikely, given the lack of association between graft age and
graft survival. There was also no benefit in the subset of
patients with ‘virgin’ grafts. Moreover, ultrasound surveil-
lance would be of limited use, if it is only beneficial for
incident grafts or those without prior interventions. Finally, it
is possible that we might have detected a potential benefit of
ultrasound surveillance with a larger sample size. However,
this appears unlikely, given that both the cumulative and
thrombosis-free graft survival curves were virtually super-
imposable between the two treatment groups (Figures 2 and 3).
Our findings do not preclude the possibility that
angioplasty is helpful in improving graft outcomes in a
subset of patients with graft stenosis. Another subset of
patients with graft stenosis will not progress to thrombosis
even without intervention; in those patients, angioplasty is
superfluous. Finally, there is a third group in which
angioplasty may accelerate graft failure. The effect of
introducing a program of graft monitoring for stenosis in
an unselected hemodialysis population is no net change in
overall graft outcomes. A lack of increase in access blood flow
after angioplasty predicts grafts that are likely to fail;20
however, the procedure has to be performed before that
assessment can be made. At present, there is no reliable
diagnostic test that can be applied before the intervention to
identify those patients in whom prophylactic angioplasty
might be beneficial.
The present study has several limitations. First, it was
conducted at a single dialysis center, and the results may not
generalize to some dialysis centers. Second, the ultrasound
surveillance was performed every 4 months; we cannot
exclude the possibility that more frequent ultrasound
surveillance of grafts may improve graft longevity. Third,
owing to our aggressive clinical monitoring program, the rate
of pre-emptive angioplasty in the control group was quite
high (0.64 per year), similar to the rate reported by Moist
et al.,13 but considerably higher than the rate of 0.22 per year
reported by Ram et al.12 It may well be that a percutaneous
transluminal angioplasty rate of 0.6 per year confers all the
benefit that pre-emptive percutaneous transluminal angio-
plasty can provide. However, in that case, achieving this
frequency with free clinical monitoring is more cost-effective
than achieving it by costly surveillance methods, such as flow
monitoring or ultrasound.
In summary, the addition of routine ultrasound surveil-
lance, in addition to clinical monitoring, was very effective in
early detection of graft stenosis. However, the increase in pre-
emptive angioplasties resulting from ultrasound surveillance
did not appear to prevent graft thrombosis or increase graft
longevity in the present study. This study was underpowered
to detect a more modest clinical benefit of ultrasound
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surveillance on graft survival, which would require perform-
ing a larger, multicenter randomized clinical trial. Such a trial
is critical to determine whether the added cost of periodic
ultrasound examinations and more angioplasties is cost-
effective. Finally, pharmacologic prophylaxis of myointimal
hyperplasia may be beneficial in the prevention of graft
stenosis.
MATERIALS AND METHODS
Enrollment criteria
Patients were eligible for enrollment into the study if they had been
on maintenance hemodialysis for at least 3 months, were currently
dialyzing at an outpatient hemodialysis unit affiliated with
University of Alabama at Birmingham and were using an upper
extremity A-V graft. The graft age had to be between 1 and 24
months, with no graft interventions in the preceding month, and
none scheduled for the future. Patients were excluded if they had
severe or unstable medical illness (class IV congestive heart failure;
chronic pulmonary disease requiring home oxygen; hepatic
encephalopathy; active malignancy being treated with chemotherapy
or radiation therapy; AIDS; or active tuberculosis). Patients were
also excluded if they were scheduled for a living-donor renal
transplant or if they were enrolled in another interventional research
study. Patients meeting these inclusion and exclusion criteria were
approached about participation in this clinical trial. Study
enrollment occurred between 16 November 1999 and 13 November
2002, and the study was terminated 2 years after enrolling the last
subject (13 November 2004).
Study randomization
Before randomization, each subject signed a written, informed
consent, as approved by our local Institutional Review Board.
Patients were allocated 1:1 to the ultrasound and control groups.
Randomization was stratified by hemodialysis unit, and blocked to
ensure balance between the treatment groups. Subject assignment
was determined by having the Study Coordinator open sequentially
numbered, opaque envelopes.
Study procedures
All patients enrolled in this study (ultrasound and control groups)
had their grafts monitored clinically by the dialysis nurses and
nephrologists, according to the standard procedures followed at our
dialysis center.16 The clinical monitoring tools fell into three broad
categories: (1) abnormal physical examination (absent thrill,
abnormal graft auscultation or edema distal to the graft); (2)
abnormalities related to the dialysis session (difficulty in cannu-
lation, aspiration of clots, inability to achieve the target dialysis
blood flow or prolonged bleeding (430 min) from the needle sites);
or (3) unexplained, sustained fall (40.2 units) in delivered Kt/V,
despite following a constant dialysis prescription. A fistulogram was
scheduled in both groups whenever there was a clinical suspicion for
hemodynamically significant graft stenosis.
The subjects in the ultrasound group, in addition to having
clinical monitoring, also underwent standardized Duplex ultra-
sound monitoring of their graft for evidence of hemodynamically
significant stenosis, as previously described by us.17 The ultrasounds
were performed shortly after randomization, and then every 4
months. All ultrasounds were performed by one of three
sonographers in a vascular laboratory accredited by the American
College of Radiology. All studies were interpreted by a single
experienced radiologist (MLR). A peak systolic velocity was
calculated at the graft venous anastomosis and at any other area
of visual stenosis or color Doppler aliasing, using a protocol
previously published by us.17 A volume flow was measured using
Doppler ultrasound. A peak systolic velocity ratio X2.0 at the
stenotic site compared with the peak systolic velocity immediately
upstream was the primary criterion used to diagnose a stenosis. If
the peak systolic velocity ratio wasX2.0, visual inspection with gray
scale and color Doppler ultrasound was used to confirm a stenosis.
The measured volume flow was used as a secondary supportive
indicator of potential graft stenosis. Subjects whose ultrasound
suggested significant stenosis underwent a diagnostic fistulogram
within 1 week. If a significant (450%) stenosis was confirmed,
angioplasty was performed at the same session.
Access management
All A-V grafts were placed by one of three transplant surgeons on the
University of Alabama at Birmingham faculty, after reviewing the
results of preoperative vascular mapping.26,27 Fistulograms, angio-
plasties, and thrombectomies of grafts were performed by one of
three interventional radiologists on the University of Alabama at
Birmingham faculty. A single radiologist (RFO) quantified the
degree of stenosis before and after each angioplasty. In addition, the
radiologists recorded the patient’s intra-access pressure and systemic
pressure before and immediately after the intervention. We have
previously documented that the intra-access to systemic systolic
pressure ratio is predictive of subsequent primary graft patency.16,28
If the angioplasty was technically unsuccessful, the patient was
referred for a surgical revision of the graft. Patients with frequent
graft thrombosis were also referred for elective surgical revision, at
the discretion of their nephrologists. Infected grafts that did not
improve with systemic antibiotics were removed surgically.
Study outcomes
The primary outcome was graft survival (time from randomization
to permanent failure of the graft, despite radiologic or surgical
salvage procedures). The secondary outcome was thrombosis-free
graft survival (time from randomization to first graft thrombosis or
permanent graft failure). Other outcomes measured included the
overall frequency of graft angioplasty, thrombosis or surgical
revision.
Statistical methods
Power calculations were performed on the basis of data obtained
from prior University of Alabama at Birmingham experience with
graft outcomes. The estimated sample size of 126 patients, evenly
divided between the two groups, was sufficient to detect a doubling
in median graft survival from 16 months on the control arm to 32
months on the ultrasound arm, assuming an exponential distribu-
tion, 2 years of accrual, 2 years of follow-up, two-sided significance
level of 0.05, and power of 0.80. As specified in the protocol, an
interim analysis was conducted after half of the patients had
completed 2 years of follow-up. This analysis was performed after 3
years, at which time 29 graft failures had been observed. Because a
maximum of 69 graft failures were expected under the null
hypothesis, the significance level required for early study termi-
nation following the interim analysis was 0.001 using the O’Brien-
Fleming boundaries. The impact of the interim analysis on the
overall significance level was minimal, and the significance level for
the final analysis was 0.05. Because the sample size may have missed
a more modest benefit of ultrasound surveillance on cumulative
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graft survival, we also evaluated time to graft thrombosis as a
secondary outcome of the study.
Fisher’s exact test and the Wilcoxon rank sum test were used to
compare the two groups with respect to categorical and continuous
measures, respectively. The product limit method was used to
describe the graft survival and thrombosis-free survival for each
group, and subjects were censored at the time of death, transplant,
or relocation to a non-participating dialysis unit. Survival curves
were compared using the log-rank test. The proportional hazards
model was used to evaluate the role of covariates on graft survival
and thrombosis-free survival.
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